{
    "pmcid": "11254834",
    "qa_pairs": {
        "What are the three categories of generative models for antibody design discussed in the paper?": [
            "Sequence-Generating Models, Structure-Generating Models, Hybrid Models",
            "Sequence-Generating Models, Function-Generating Models, Hybrid Models",
            "Structure-Generating Models, Function-Generating Models, Hybrid Models",
            "Sequence-Generating Models, Structure-Generating Models, Function-Generating Models"
        ],
        "What is a significant challenge mentioned in the paper regarding the integration of antigen information into generative models?": [
            "Improving specificity and affinity predictions",
            "Increasing the speed of sequence generation",
            "Enhancing the diversity of generated antibodies",
            "Reducing computational costs"
        ],
        "What is highlighted as a potential advantage of nanobodies over traditional antibodies in targeting the SARS-CoV-2 spike protein?": [
            "They are smaller and more stable",
            "They have higher binding affinity",
            "They are easier to produce",
            "They have broader cross-reactivity"
        ],
        "Which models are specifically mentioned as focusing on designing antibodies targeting specific epitopes on the SARS-CoV-2 spike protein?": [
            "EAGLE and DiffAb",
            "AntiBARTy and IgLM",
            "IG-VAE and IgFold",
            "AlphaFold 3 and HelixFold-Multimer"
        ],
        "Which region is emphasized as critical for antigen binding due to its high variability?": [
            "CDRH3",
            "CDRH1",
            "CDRL3",
            "CDRL1"
        ]
    }
}